Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)
作者
Nirav Niranjan Shah,Richard Thomas Maziarz,Caron Alyce Jacobson,Monalisa Ghosh,Iris Isufi,Matthew L. Ulrickson,Miguel‐Angel Perales,Matthew Alexander Lunning,Nancy M. Hardy,Anna Wijatyk,Marek Ancukiewicz,Mrs. Madhavi Nallewar,Kimberly C. Coleman,Bethany Cheree Prudner,Esther Eromosele,Remigiusz Kaleta,David Bernard Miklos